These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 26908294)

  • 1. Disruption of vascular endothelial homeostasis in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The dynamic roles of angiopoietin-1 and -2.
    Tasaki Y; Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Wada T; Yachie A
    Cytokine; 2016 Apr; 80():1-6. PubMed ID: 26908294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
    Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Clin Exp Immunol; 2018 Mar; 191(3):349-355. PubMed ID: 28815559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis.
    Sakumura N; Shimizu M; Mizuta M; Inoue N; Nakagishi Y; Yachie A
    Cytokine; 2018 Oct; 110():459-465. PubMed ID: 29801971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiopoietin-1 and -2 as markers for disease severity in hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli.
    Shimizu M; Inoue N; Kuroda M; Mizuta M; Sugimoto N; Kaneda H; Ohta K; Yachie A
    Clin Exp Nephrol; 2017 Feb; 21(1):76-82. PubMed ID: 26945868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
    J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
    Put K; Avau A; Brisse E; Mitera T; Put S; Proost P; Bader-Meunier B; Westhovens R; Van den Eynde BJ; Orabona C; Fallarino F; De Somer L; Tousseyn T; Quartier P; Wouters C; Matthys P
    Rheumatology (Oxford); 2015 Aug; 54(8):1507-17. PubMed ID: 25767156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Davì S; Minoia F; Pistorio A; Horne A; Consolaro A; Rosina S; Bovis F; Cimaz R; Gamir ML; Ilowite NT; Kone-Paut I; Feitosa de Oliveira SK; McCurdy D; Silva CA; Sztajnbok F; Tsitsami E; Unsal E; Weiss JE; Wulffraat N; Abinun M; Aggarwal A; Apaz MT; Astigarraga I; Corona F; Cuttica R; D'Angelo G; Eisenstein EM; Hashad S; Lepore L; Mulaosmanovic V; Nielsen S; Prahalad S; Rigante D; Stanevicha V; Sterba G; Susic G; Takei S; Trauzeddel R; Zletni M; Ruperto N; Martini A; Cron RQ; Ravelli A;
    Arthritis Rheumatol; 2014 Oct; 66(10):2871-80. PubMed ID: 25044674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis.
    Reddy VV; Myles A; Cheekatla SS; Singh S; Aggarwal A
    Int J Rheum Dis; 2014 Mar; 17(3):261-7. PubMed ID: 24417800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Shimizu M; Nakagishi Y; Inoue N; Mizuta M; Ko G; Saikawa Y; Kubota T; Yamasaki Y; Takei S; Yachie A
    Clin Immunol; 2015 Oct; 160(2):277-81. PubMed ID: 26101092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
    Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
    Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Bracaglia C; de Graaf K; Pires Marafon D; Guilhot F; Ferlin W; Prencipe G; Caiello I; Davì S; Schulert G; Ravelli A; Grom AA; de Min C; De Benedetti F
    Ann Rheum Dis; 2017 Jan; 76(1):166-172. PubMed ID: 27296321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis.
    Shimizu M; Yokoyama T; Yamada K; Kaneda H; Wada H; Wada T; Toma T; Ohta K; Kasahara Y; Yachie A
    Rheumatology (Oxford); 2010 Sep; 49(9):1645-53. PubMed ID: 20472718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children.
    Mizuta M; Shimizu M; Irabu H; Usami M; Inoue N; Nakagishi Y; Wada T; Yachie A
    Rheumatology (Oxford); 2021 Jan; 60(1):231-238. PubMed ID: 32681176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
    Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
    World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages.
    Shimizu M; Yachie A
    Cytokine; 2012 Oct; 60(1):226-32. PubMed ID: 22682876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Takakura M; Shimizu M; Irabu H; Sakumura N; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Clin Immunol; 2019 Nov; 208():108252. PubMed ID: 31449879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
    Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Pediatr Res; 2020 Dec; 88(6):934-939. PubMed ID: 32184444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
    Huang S; Liu Y; Yan W; Zhang T; Wang P; Zhu M; Zhang X; Zhou P; Fan Z; Yu H
    Pediatr Rheumatol Online J; 2024 May; 22(1):58. PubMed ID: 38783316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis.
    Kaufman KM; Linghu B; Szustakowski JD; Husami A; Yang F; Zhang K; Filipovich AH; Fall N; Harley JB; Nirmala NR; Grom AA
    Arthritis Rheumatol; 2014 Dec; 66(12):3486-95. PubMed ID: 25047945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
    Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.